Trial Profile
Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets and Evaluation of the Potential Impact of Concomitant Food Intake on the Relative Bioavailability of GKT137831 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs Setanaxib (Primary)
- Indications Bile duct diseases; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Squamous cell cancer
- Focus Pharmacokinetics
- Sponsors Calliditas Therapeutics
- 11 Feb 2019 Status changed from recruiting to completed.
- 29 Jan 2019 Status changed from not yet recruiting to recruiting.
- 21 Nov 2018 New trial record